GLOW (BPC-157 / TB-4 / GHK-Cu)

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

GLOW Blend —Triple-Peptide Regenerative Matrix | BPC-157 / TB-500 / GHK-Cu

GLOW is a pre-formulated blend of three mechanistically distinct research peptides — BPC-157, Thymosin Beta-4 Fragment (TB-500), and GHK-Cu — combined in a single lyophilized vial to support multi-pathway investigation of tissue repair, vascular remodeling, extracellular matrix regulation, and cellular regeneration. Each component operates through a non-redundant primary mechanism: BPC-157 modulates nitric oxide and VEGF signaling; TB-500 governs cytoskeletal dynamics through actin sequestration; and GHK-Cu coordinates redox homeostasis and gene-level regulation of structural protein synthesis. The rationale for co-formulation is mechanistic complementarity — the three peptides collectively address the initiation, proliferation, and remodeling phases of tissue repair in ways no single peptide replicates alone. GLOW is supplied as a filler-free lyophilized powder for researchers investigating complex regenerative endpoints requiring simultaneous modulation of angiogenic, cytoskeletal, and matrix-remodeling pathways.

Why GLOW’s Three-Component Architecture Is Distinctive

Single-peptide models are limited by pathway specificity. GLOW was designed around a phase-based repair logic: each component maps to a different stage of the healing cascade, and each operates through a primary intracellular mechanism the others do not replicate.

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide derived from a gastric cytoprotective sequence. Its primary mechanism is upregulation of VEGFR2 expression — notably without altering VEGF-A levels — and activation of the FAK-paxillin pathway, which dramatically increases phosphorylation of focal adhesion kinase and paxillin, driving fibroblast adhesion and migration. It also modulates eNOS activity via Src-Caveolin-1 interactions, stabilizing vascular tone and initiating angiogenesis at injury sites. BPC-157 is the blend’s primary driver of local tissue stabilization and pro-angiogenic signaling in the early-to-mid proliferative phase.

TB-500 (Thymosin Beta-4 Fragment) operates through G-actin sequestration — binding monomeric actin in a 1:1 ratio to regulate cytoskeletal availability, cell motility, and directional migration. Separately, it modulates NF-κB, PI3K/Akt/eNOS, and TGF-β signaling cascades, providing systemic reach that complements BPC-157’s more localized activity. TB-500 is the blend’s primary driver of cell migration, cytoskeletal reorganization, and systemic vascular remodeling.

GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex) contributes the broadest genomic reach of the three, with documented modulation of gene expression affecting an estimated 31% of the human genome. At the structural level, it stimulates collagen and decorin synthesis (decorin production increased ~302% in fibroblast models), upregulates VEGF and FGF, and balances MMP/TIMP activity to regulate extracellular matrix turnover. GHK-Cu is the blend’s primary driver of the remodeling phase — ensuring structural integrity and organized collagen deposition after vascular and cellular repair has been initiated by the other two components.

Research Applications

• Multi-phase wound healing studies examining angiogenesis, reepithelialization, and collagen remodeling as sequential processes
• Musculoskeletal injury models (tendon, ligament, muscle) requiring both local and systemic regenerative signaling
• Dermal and connective tissue repair research, including scar quality and skin structural integrity endpoints
• Inflammatory resolution studies utilizing the combined anti-inflammatory profiles of all three components (TNF-α, IL-6 suppression; eNOS stabilization; NF-κB modulation)
• Vascular repair models investigating convergent angiogenic mechanisms (VEGFR2 upregulation via BPC-157; endothelial progenitor mobilization via TB-500; VEGF/FGF stimulation via GHK-Cu)
• Age-related tissue decline models where declining GHK-Cu plasma levels and impaired actin dynamics are co-variables of interest
• Neurovascular and neuroprotective research: GHK-Cu’s NGF/NT-3/NT-4 stimulation, BPC-157’s dopaminergic modulation, and TB-500’s caspase-3 inhibition and oligodendrocyte differentiation support multi-target neurological study designs
• Protocol simplification studies comparing single-peptide vs. blended multi-pathway administration in equivalent dose models

Specifications

Reconstitution

Formula: Total mg ÷ Volume added (mL) = Concentration (mg/mL)

For the 70mg vial:

• 70mg + 3.5mL BAC water = 20mg/mL (BPC-157: ~2.86mg/mL | TB-500: ~2.86mg/mL | GHK-Cu: ~14.3mg/mL)
• 70mg + 7mL BAC water = 10mg/mL (BPC-157: ~1.43mg/mL | TB-500: ~1.43mg/mL | GHK-Cu: ~7.14mg/mL)

Add BAC water slowly down the side of the vial. Swirl gently — do not shake. Reconstituted solution should be clear to very pale blue (characteristic of the GHK-Cu copper chelate). Any cloudiness, particulate matter, or unusual color change indicates degradation; discard and do not use.

Post-reconstitution storage: Refrigerate at 2–8°C. Use within 28 days. Do not freeze reconstituted solution. GHK-Cu is the least stable component post-reconstitution — solution should be used within the 28-day window without extension.

Protocol Notes

Research dosing for blended formulations varies by study design. The following represents a titration framework observed in preclinical literature and investigator-initiated protocols:

• Starting administration volume: Calculate based on target per-component dose; most protocols anchor to BPC-157 or TB-500 dosing (100–250mcg/component) as the rate-limiting reference
• Frequency: BPC-157 and GHK-Cu are typically administered daily or 5x/week in active-phase protocols; TB-500 is commonly front-loaded (2x/week for 4–6 weeks) then transitioned to weekly maintenance
• Route: Subcutaneous injection; local/perilesional injection used in site-specific musculoskeletal models
• Cycle length: Active phase 4–8 weeks; maintenance or extension phase up to 12–16 weeks depending on endpoint
• Washout: 4–6 weeks between cycles; longer washout recommended for extended protocols

Commonly observed effects in research models:

Vascular / Tissue: Accelerated wound closure; enhanced reepithelialization; improved collagen density and organization; reduced fibrosis; angiogenic activity at both local (BPC-157/GHK-Cu VEGF axis) and systemic (TB-500 endothelial progenitor mobilization) levels

Inflammatory / Immune: Reduction in TNF-α, IL-6, and pro-inflammatory cytokine panels; NF-κB suppression (TB-500, GHK-Cu); eNOS stabilization and nitric oxide pathway normalization (BPC-157); macrophage and mast cell chemoattraction (GHK-Cu)

Structural / Matrix: Increased decorin and glycosaminoglycan synthesis; MMP/TIMP rebalancing; improved ECM organization in dermal and connective tissue models; FAK-paxillin-mediated fibroblast adhesion and migration

Neurological (emerging): NGF, NT-3, and NT-4 stimulation (GHK-Cu); dopaminergic modulation without direct receptor binding (BPC-157); oligodendrocyte progenitor differentiation and caspase-3 inhibition (TB-500)

Research Stacks

GLOW is commonly paired in research settings with:

• BPC-157 — Additional BPC-157 is studied alongside the full GLOW blend to examine dose-dependent angiogenic and growth factor effects when the BPC-157 component is supplemented beyond the fixed ratio in the blend.
• TB-500 — Supplemental TB-500 is paired with GLOW in research models where the actin-modulating and anti-inflammatory properties of Thymosin Beta-4 are assessed at higher concentrations than available within the fixed-ratio blend.
• GHK-Cu — Additional GHK-Cu is co-studied with GLOW to characterize dose-response relationships for the copper tripeptide’s collagen-stimulating and antioxidant-gene-regulating effects across tissue and skin repair models.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.